---
title: "Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. (301126.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301126.SZ.md"
symbol: "301126.SZ"
name: "Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd."
industry: "Health Care Distributors"
datetime: "2026-05-20T22:34:07.812Z"
locales:
  - [en](https://longbridge.com/en/quote/301126.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301126.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301126.SZ.md)
---

# Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. (301126.SZ)

## Company Overview

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages, drinks, and probiotic beverages; and cleansing and care products. In addition, it provides pharmaceutical logistics services; and operates reproductive hospitals.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.djwk.com.cn](https://www.djwk.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.76)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 23 / 23 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.46% |  |
| Net Profit YoY | -2430.58% |  |
| P/B Ratio | 1.62 |  |
| Dividend Ratio | 0.88% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2432184282.33 |  |
| Revenue | 5237918034.42 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 17.23% | D |
| Revenue YoY | -0.46% | D |
| Net Profit YoY | -2430.58% | E |
| Total Assets YoY | -0.78% | D |
| Net Assets YoY | -13.77% | E |
| Cash Flow Margin | 6.55% | D |
| OCF YoY | -0.46% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 74.92% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.46%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2430.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.88%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2432184282.33",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5237918034.42",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "17.23%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.46%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2430.58%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.78%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-13.77%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "6.55%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-0.46%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "74.92%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.00 | 22/23 | 253.10 | 227.93 | 218.54 |
| PB | 1.60 | 16/23 | 1.54 | 1.42 | 1.32 |
| PS (TTM) | 0.46 | 14/23 | 0.49 | 0.46 | 0.44 |
| Dividend Yield | 0.89% | 18/23 | 0.86% | 0.73% | 0.66% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301126.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301126.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301126.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301126.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**